Background: Little is known about quality of life and functional status of patients with terminally ill head and neck cancers. Methods: We conducted a multicenter, prospective, observational study to examine quality of life and functional status in terminally ill head and neck cancer patients. Results: Of the 100 patients meeting inclusion criteria, 72 were observed until death. There was no significant difference in the quality of life score between baseline and Week 3. Forty patients (54.9%) could speak and 22 patients (30.5%) could have oral intake upon study entry. Fifty-three patients (74.6%) received enteral nutrition. Twenty-six patients (36.6%) required dressing changes for fungating tumors. The route of nutritional intake (nasogastric tube vs. percutaneous gastric tube) might be predictive for the duration of hospital stay (64 vs. 21 days, P = 0.0372). Conclusion: There was no significant relationship between quality of life and functional status seen in this study. Feeding tube type could have the most impact on quality of life.
Introduction
Each year, head and neck cancer (HNC) affect up to 600 000 people worldwide (1) . In Japan, there were an estimated 29 200 new cases of HNC and 9209 deaths due to HNC, which accounted for approximately 4% and 3% of all cancers, respectively (2) . Many patients have advanced disease at diagnosis, and their prognosis remains poor despite the emergence of new therapeutic options over the last few decades (3) (4) (5) (6) (7) . Intensive treatment, which is said to be at 'the upper limit of human tolerance,' (8) has generated problems such as acute and late treatment-related toxicity (9, 10) . In general, patients with incurable HNC have one or more following specific symptoms: (11) (12) (13) (14) (15) (16) (17) (i) functional symptoms associated with eating, speaking and breathing caused by the anatomical location of the tumor (e.g. dysphagia and dyspnea); (ii) late toxicity and comorbidity from previous treatment (e.g. aphonia and xerostomia); (iii) complications from medical devices (e.g. feeding tube and tracheostomy cannula); and (iv) symptoms caused by a fungating tumor (e.g. cosmetic change, malodor and bleeding). These symptoms substantially reduce quality of life (QOL) as well as physical functioning.
Furthermore, many regional general hospitals are reluctant to care for these terminally ill patients because they represent only a small percentage of patients with cancer (12) and medical staff are not used to treating and caring for the symptoms described above.
Most of these symptoms are caused by locoregional lesions. Visceral metastasis is less frequent in HNC than in other cancers (17) . Therefore, predicting prognosis accurately is often difficult because lung, liver, or kidney function might remain intact, even if locoregional lesions impair respiration and consciousness. Consequently, few patients with incurable HNCs are seen in a general hospital or hospice setting or are cared for by a general practitioner. In Japan, many patients are seen in institutions with experienced multidisciplinary teams such as tertiary cancer centers. However, no data reflecting real-world practice have been reported so far.
To the best of our knowledge, there have been no prospective studies that focus on the relationship between QOL and functional status (FS) based on both patient reported outcomes (PROs) and clinician reported outcome (CROs) in terminally ill HNC patients. We conducted a nation-wide, cross-sectional, observational study and herein report the results.
Material and methods

Study design and eligibility
This was a nation-wide, prospective, observational study. Eleven cancer centers and university hospitals that treat a large number of HNC patients in Japan participated in this study.
Patients met following criteria were enrolled: (i) age ≥20 years, (ii) diagnosis of incurable HNC (cancer of the nasopharynx, oropharynx, hypopharynx, oral cavity, larynx, nasal and paranasal sinus, thyroid and salivary gland), (iii) inpatient status at study enrollment, (iv) no surgery, radiotherapy or chemotherapy within 2 weeks of study enrollment and (v) ability to complete the questionnaire without assistance. Patients who cannot complete the questionnaire due to cognitive impairment at baseline were excluded. Patients received care consistent with the current standard of care at each institution and received no special interventions in association with this study.
Observation schedule
PRO and CRO data were collected weekly during Weeks 1-4 of observation and every 2 weeks thereafter. Observation was terminated when the patient died, was transferred to another hospital, or the observation period exceeded 6 months.
Outcome measures
The following PROs and CROs were assessed. They were chosen based on consensus among experts on HNC treatment participating in this study.
PRO measures
The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 15-Palliative Care (C15-PAL) (18) was used to assess QOL. It is a shorter version of the EORTC QLQ-Core 30 (C30), a comprehensive QOL evaluation tool for cancer patients (19, 20) . EORTC QLQ-C15-PAL consists of 15 items, including a global health status (GHS)/QOL item, a five-item functioning subscale (physical, role, emotional, cognitive and social functioning), and a nine-item symptom subscale (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). Scores for global health status and the functioning and symptom subscales were calculated according to the scoring manual (21) . Scores range between 0 and 100, with higher scores (≥60) indicating better functioning in the GHS/QOL item and functioning subscales and lower scores (≤40) indicating better physical condition in the symptom subscales.
CRO measures
CRO measures consisted of three parameters regarding tumor location and condition (anatomical location of the tumor in the HNC region, fungating tumor and bleeding), four parameters regarding airway condition (respiratory tract pattern, need for a cuffed endotracheal tube, presence of pulmonary metastasis or pleural effusion, and presence of noisy secretions in the respiratory tract), one parameter regarding route of nutritional intake, and two other parameters regarding speech and facial edema.
Study objectives
The primary endpoint was the change in GHS/QOL (EORTC QLQ-C15-PAL item 15) between Week 3 and baseline. Secondary endpoints included the proportion of the following QOL-related variables specific to HNC: respiratory tract pattern, tumor location, bleeding, pulmonary metastasis, nutritional route, ability to make speech, facial edema and presence of noise due to excessive respiratory tract secretions. Overall survival, length of hospital stay, and attrition rate were recorded as well.
Statistical considerations
On the basis of a similar study (22) , the mean (± SD) change in the primary endpoint (EORTC QLQ-C15-PAL) between Week 3 and baseline was estimated to be 0.5 ± 1.5 points. With an assumed attrition rate of 40% due to patient death or worsening condition in a palliative setting (23) , 100 patients were required for evaluation of the primary outcome with a one-sided significance level of 0.05 and statistical power of 80%. The mean change between Week 3 and baseline was estimated and analyzed with one-sided paired t-tests.
Ethical considerations
The study protocol conformed to the Declaration of Helsinki and the Ethical Guidelines for Epidemiology Research. The institutional review boards of all participating institutions granted ethical approval. Written informed consent was obtained from all study participants.
Trial registration
This study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) under UMIN000004728.
Results
Patient characteristics
Between January 2011 and October 2013, 100 patients at 11 institutions met the inclusion criteria and were enrolled in this study. The median age was 69 years (range, 37-94). There were 79 (79%) males and 21 (21%) females. Approximately half of the patients had poor performance status (PS) (PS 3 or 4, 55%). The distribution of primary sites was: lip and oral cavity, 31%; hypopharynx, 26%; oropharynx, 12%; and other, 32%. Most patients (91%) had metastatic lesions, mostly consisting of locoregional metastases. Approximately two-thirds (67%) of patients had cervical or retropharyngeal lymph node metastasis. Distant metastasis were mainly seen in the lung (32%), followed by bone (11%) ( Table 1) .
Of the 100 patients, 72 (72%) were observed until death (Fig. 1) . Median length of survival from study entry was 33.5 days (range, 0-167). Out of 72 patients, 48 (67%) could answer EORTC QLQ-C15-PAL until 1 week before death. Data on the primary endpoint, change in GHS/QOL as assessed by EORTC QLQ-C15-PAL between Week 3 and baseline, were collected from 48 (67%) of 72 patients.
PRO
The GHS/QOL score from EORTC QLQ-C15-PAL did not change significantly between baseline and Week 3 (Fig. 2) . In addition, secondary endpoints evaluated with the EORTC PAL-15 did not differ significantly between baseline and Week 3 (Fig. 3) .
CRO
Speech ability and airway Thirty-two patients (44.4%) were breathing via a tracheostoma. Laryngeal phonation was possible at baseline in 40 (55.6%) of 72 patients and 36 (50.0%) patients on dying.
Between enrollment and just before death, no difference was observed in the respiratory tract pattern or need for a cuffed endotracheal tube. The proportion of patients requiring a cuffed endotracheal tube was higher among those with oral, hypopharyngeal or laryngeal cancer and those with metastasis to cervical lymph nodes (Table 2) . Rattle due to tracheal secretions was more commonly observed in patients with tracheotomy sites than in patients with permanent stomas; however, the degree of dyspnea did not differ between these two groups (Tables 3 and 4) .
Route of nutritional intake
Enteral feeding was required by 53 (73.6%) of 72 patients at baseline and by 43 patients (59.7%) just before death. Oral feeding was possible for 22 (30.6%) of patients at baseline but in only 17 patients (23.6%) just before death. For patients fed through a percutaneous gastrostomy tube (PEG), the time between study enrollment and death was significantly shorter than for patients fed through a nasogastric tube. Median duration of hospitalization was significantly shorter for gastrostomy-fed patients (21 days) than for nasogastric tube-fed patients (64 days, P < 0.05, Wilcoxon rank-sum test) (Fig. 4) .
Facial edema
Facial edema was present in 17 patients (23.6%) at baseline and in 26 patients (36.1%) just before death.
Dressing change and bleeding
Fungating tumors in the head and neck region requiring dressing changes were present in 22 (30.6%) of 72 patients at the time of study entry and in 26 patients (36.1%) just before death. Five patients (6.9%) had severe bleeding, including two patients (2.8%) with fatal bleeding and three patients (4.2%) had hemorrhagic shock.
Discussion
This study was conducted in tertiary cancer centers and university hospitals that had expertize in the treatment of HNC in Japan.
Terminally ill HNC patients are not rare, but prospective, high- quality data on QOL and FS are limited. We were able to investigate both PROs and CROs in a frail population, with a comparable attrition rate to that in a previous report of terminally ill cancer patients (23) . During study design, we hypothesized that QOL of patients with incurable HNC worsens over time, and this study was planned to detect a difference in QOL between Week 3 and baseline as the primary endpoint. We also explored whether FS specific to HNC might influence QOL. However, we found that QOL, as assessed with the EORTC QLQ-C15-PAL, did not change significantly between baseline and 3 weeks in a patient population with poor prognosis (median survival, 33.5 days). This may suggest that in patients with HNC, QOL does not decline substantially in the last month of life. On the other hand, this does not necessarily reflect that patient QOL was maintained at a high level. QOL might have plateaued at a low level before the cancer became incurable, but this study was not planned to detect this possibility. Therefore, the observation period might have been too short to clarify the change in QOL among HNC patients, and long-term longitudinal observation is warranted.
The head and neck region consists of the face, eyes, ears, nose, mouth and throat, all of which are essential organs for daily living. Impairment of just one of these organs greatly reduces QOL. We investigated the prevalence of impairments specifically related to breathing, speaking, eating, and cosmetic functions.
In the present study, approximately half (47%) of patients breathed through a tracheostoma on enrollment, of which half (26%) required an endotracheal cannula. We had anticipated that the QOL of patients unable to speak and requiring an endotracheal cannula would be worse than that of patients who can speak and did not require a cannula, but we observed no clear difference between these groups. This lack of difference may possibly be explained by the level of hospital care provided by experts accustomed to treating various conditions of the respiratory tract.
Eating is one of the most important factors influencing on QOL. We hypothesized that QOL differs among patients receiving nutrition through different routes. However, we did not find a significant difference in EORTC QLQ-C15-PAL between PEG-fed and nasogastric tube-fed patients. However, in this study, the median period of hospitalization was significantly shorter for gastrostomy-fed patients than for nasogastric tube-fed patients (21 vs. 64 days). Although artificial nutrition in terminally ill cancer patients is controversial (24, 25) , this difference might reflect the fact that patients with a PEG tube were able to receive nutrition and medications as long as possible before hospitalization. In other words, patients without a PEG tube may have been hospitalized earlier due to malnutrition than patients with a PEG tube. This is a hypothesis raised by the results of this study, which requires confirmation in a future study.
Fungating tumors are commonly found in terminally ill HNC patients. It is associated several QOL-deteriorating symptoms such as malodor, exudate, hemorrhage, pain, mass effect, esthetic distress, pruritus and crusting (26) . Hemorrhage from the neck is a frightening event that makes patients and their family members imagine death, regardless of whether the bleeding is massive or not. Fatal hemorrhage has been observed in 3-4% of all HNC patients in another study (27) ; our results are similar. In the present study, dressing changes were required in 26 of 71 patients (37%) and likely added to the burden on caregivers. Although these factors did not affect QOL in this study, further research is needed.
In our study, we were able to follow more than 70% of patients until death. Therefore, we observed how patients with HNC live during the last month of life in an acute hospital setting, which is the real-world experience in Japan. The majority of terminally ill HNC patients receive care at specialized cancer centers, which might be distant from their home. Place of death is one of the quality indicators for dying. Although this was not an endpoint of this study, our study suggests that many patients with HNC die in an acute hospital. Generally, death in the acute hospital setting is less preferable than in a hospice or at home (28) . Thus, we could say that quality of dying in HNC patients in Japan remains poor. In patients fed through a percutaneous gastrostomy tube, the length of time between hospitalization and death was significantly shorter than in patients fed through a nasogastric tube. The definition of the event was death and the censored events were hospital discharge and stop observation.
Our study has a few limitations and the data should be interpreted with caution. The modest sample size made it difficult to detect small differences in QOL in a frail population. In addition, the subjects were limited to inpatients. A previous study that included families of patients who died of HNC found that intervention by specialized palliative care teams could alleviate symptoms and reduce the duration of hospitalization in patients with incurable HNC, allowing them to die outside the hospital (29) .
Despite these limitations, we shed light on the lives of terminally ill HNC patients. How they live at home and what functions affect QOL the most were not clearly delineated. Therefore, future research that can clarify these points is warranted. Our data suggests that route of nutrition intake may play a role in QOL, so we are planning a study that specifically focuses on the role of PEG feeding in patients with incurable HNC. In conclusion, we have clarified the QOL during the last month of HNC patients. Of the FS examined based on CROs, feeding tube type could have the most impact on QOL.
